Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15174510 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL1854662 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL1312674 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL553296 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL2410467 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL15174082 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL2405665 | 1.00 | HSP90AA1 (0.54) | HSP90AA1SPHK2SPHK1CES2CES1 | |
| SCHEMBL2760951 | 0.97 | — | — | |
| SCHEMBL564268 | 0.90 | — | — | |
| SCHEMBL23588015 | 0.88 | PTPN7 (0.53) | HSP90AA1SPHK2SPHK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| EP-2822548-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | University Of Virginia Patent Foundation (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013119946-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-1203767-B1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER LAMBERT CO (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| US-5693657-A | USEFUL FOR TREATING HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5441975-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, SGPL1 | HSP90AA1 2126/4885SPHK2 2/4885SPHK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.